Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis
- 1 May 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 68 (18), 1524-1528
- https://doi.org/10.1212/01.wnl.0000260699.09720.ad
Abstract
Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).Keywords
This publication has 9 references indexed in Scilit:
- PNL1 CLINICAL EFFECTIVENESS AND HEALTH OUTCOMES OF DISEASE MODIFYING TREATMENT (DMT) THAT DELAYS DISABILITY PROGRESSION IN RELAPSING/REMITTING-ONSET MULTIPLE SCLEROSIS: NOVA SCOTIA “REAL WORLD” EVIDENCEValue in Health, 2006
- Evaluation of Patients Treated with Natalizumab for Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple SclerosisValue in Health, 2004
- Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treatCMAJ : Canadian Medical Association Journal, 2004
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- The Role of Cost-effectiveness Analysis in Health and MedicineJAMA, 1996
- Cost-Effectiveness in Health and MedicinePublished by Oxford University Press (OUP) ,1996